Table Of Contents
1 Introduction 30
1.1 Objectives Of The Study 30
1.2 Market Definition 30
1.3 Overview Of Asia-Pacific Wound Care Biologics Market 30
1.4 Currency And Pricing 31
1.5 Limitation 31
1.6 Markets Covered 32
2 Market Segmentation 34
2.1 Markets Covered 34
2.2 Geographic Scope 35
2.3 Years Considered For The Study 36
2.4 Currency And Pricing 36
2.5 Research Methodology 37
2.6 Primary Interviews With Key Opinion Leaders 40
2.1 Dbmr Market Position Grid 41
2.2 Dbmr Market Challenge Matrix 42
2.3 Secondary Sources 43
2.4 Assumptions 43
3 Market Overview 44
3.1 Drivers 46
3.1.1 Increasing Cases Of Diabetic Foot Ulcers 46
3.1.2 Increasing Incidences Of Burn Cases 46
3.1.3 Rising Number Of Geriatric Population 47
3.1.4 Innovation In Wound Care Biologics 48
3.1.5 New Product Launches 50
3.2 Restrains 50
3.2.1 High Cost Of Wound Treatment And Wound Care Biologics 50
3.2.2 Risk Of Skin Substitue Failure 51
3.3 Opportunities 52
3.3.1 3D Skin Printing 52
3.3.2 Awareness Programs 53
3.4 Challenges 54
3.4.1 Lack Of Wound Management Services 54
4 Executive Summary 55
5 Premium Insights 58
6 Asia-Pacific Wound Care Biologics Market, By Product Type 63
6.1 Overview 64
6.2 Synthetic Skin Grafts 66
6.3 Growth Factors 67
6.3.1 Platelet Derived Growth Factor (Pdgf) 70
6.3.2 Platelet Rich Plasma (Prp) 70
6.3.3 Epidermal Growth Factors (Egf) 70
6.3.4 Basic Fibroblast Growth Factors (Bfgf) 71
6.3.5 Granulocyte Colony Stimulating Factor (G-Csf) 71
6.3.6 Talactoferrin Alfa 71
6.3.7 Thrombin Peptide 72
6.3.8 Keratinocy Growth Factor (Kgf) 72
6.4 Allografts 73
6.5 Xenografts 74
7 Asia-Pacific Wound Care Biologics Market, By Wound Type 76
7.1 Overview 77
7.2 Wounds 78
7.2.1 Surgical Wound 80
7.2.1.1 Skin Surgery 81
7.2.1.1.1 Wound Closure 82
7.2.1.1.2 Skin Biopsy 82
7.2.1.1.3 Skin Flap 82
7.2.1.1.4 Skin Graft 82
7.2.1.1.5 Others 82
7.2.1.2 Cosmetic Procedure 83
7.2.1.2.1 Brest Enhancement 84
7.2.1.2.2 Facial Contouring 85
7.2.1.2.3 Facial Rejuvenation; 85
7.2.1.2.4 Body Contouring 85
7.2.1.2.5 Skin Rejuvenation 85
7.2.1.2.6 Others 86
7.2.1.3 Gynecologic Procedures 86
7.2.1.3.1 Pubovaginalis Sling 86
7.2.1.3.2 Pelvic Floor Reconstruction 87
7.2.1.3.3 Rectocele Repair Surgery 87
7.2.1.3.4 Others 87
7.2.1.4 Gastrointestinal Procedure 87
7.2.1.4.1 General Gastrointestinal Surgery 88
7.2.1.4.2 Hernia 89
7.2.1.4.3 Others 89
7.2.2 Acute Wounds 90
7.2.3 Chronic Wounds 90
7.2.4 Traumatic Wounds 91
7.3 Burns 91
7.3.1 Ulcers 92
7.3.2 Diabetic Ulcers 94
7.3.3 Pressure Ulcer 94
7.3.4 Venous Ulcer 95
7.3.5 Others 95
8 Asia-Pacific Wound Care Biologics Market, By End User 96
8.1 Overview 97
8.2 Hospitals 99
8.3 Wound Care Centers 100
8.4 Ambulatory Surgical Centers 101
8.5 Clinics 103
8.6 Community Healthcare Center 104
9 Asia-Pacific Wound Care Biologics Market; Geography 105
9.1 Asia-Pacific 105
9.1.1 China 117
9.1.2 Japan 124
9.1.3 India 131
9.1.4 South Korea 138
9.1.5 Australia 145
9.1.6 Thailand 152
9.1.7 Malaysia 159
9.1.8 Singapore 166
9.1.9 Indonesia 173
9.1.10 Philippines 180
9.1.11 Rest Of Asia-Pacific 187
10 Asia-Pacific Wound Care Biologics Market, Company Landscape 188
10.1 Company Share Analysis; Asia-Pacific 188
11 Company Profile 189
11.1 Mimedx. 189
11.1.1 Company Overview 189
11.1.2 Revenue Analysis; 189
11.1.3 Company Share Analysis; 190
11.1.4 Product Portfolio 190
11.1.5 Recent Developments 191
11.2 Organogenesis Inc 192
11.2.1 Company Overview 192
11.2.2 Geographic Presence 192
11.2.3 Company Share Analysis; 193
11.2.4 Product Portfolio 193
11.2.5 Recent Developments 194
11.3 Integra Lifesciences 195
11.3.1 Company Overview 195
11.3.2 Revenue Analysis 195
11.3.3 Company Share Analysis; 196
11.3.4 Product Portfolio 196
11.3.5 Recent Developments 197
11.4 Convatec Inc. 198
11.4.1 Company Overview 198
11.4.2 Revenue Analysis 198
11.4.3 Company Share Analysis; 199
11.4.4 Product Portfolio ; 199
11.4.5 Recent Developments 199
11.5 Acell Inc. 200
11.5.1 Company Overview 200
11.5.2 Product Portfolio 200
11.5.3 Recent Developments 201
11.6 Allosource 202
11.6.1 Company Overview 202
11.6.2 Product Portfolio 202
11.6.3 Recent Developments 203
11.7 Alphatec Spine, Inc. ( A Subsidary Of Alphatec Holdings, Inc) 204
11.7.1 Company Overview 204
11.7.2 Product Portfolio 204
11.7.3 Recent Developments 204
11.8 Amnio Technology, Llc 205
11.8.1 Company Overview 205
11.8.2 Product Portfolio 205
11.8.3 Recent Developments 206
11.9 Amniox Medical, Inc. 207
11.9.1 Company Overview 207
11.9.2 Product Portfolio 207
11.9.3 Recent Developments 208
11.10 Anika Therapeutics, Inc. 209
11.10.1 Company Overview 209
11.10.2 Revenue Analysis 209
11.10.3 Product Portfolio 210
11.10.4 Recent Developments 210
11.11 Biohorizons Iph, Inc ( A Subsidary Of Henry Schein, Inc.) 211
11.11.1 Company Overview 211
11.11.2 Geographicpresence 211
11.11.3 Product Portfolio 212
11.11.4 Recent Developments 212
11.12 Kerecis 213
11.12.1 Company Overview 213
11.12.2 Geographical Presence 213
11.12.3 Product Portfolio 214
11.12.4 Recent Developments 214
11.13 Marine Polymer Technologies, Inc 215
11.13.1 Company Overview 215
11.13.2 Product Portfolio 215
11.13.3 Recent Developments 215
11.14 M?lnlycke Health Care Ab 216
11.14.1 Company Overview 216
11.14.2 Revenue Analysis 216
11.14.3 Product Portfolio 217
11.14.4 Recent Developments 217
11.15 Osiris Therapeutics, Inc. 218
11.15.1 Company Overview 218
11.15.2 Revenue Analysis 218
11.15.3 Product Portfolio 219
11.15.4 Recent Developments 219
11.16 Skye Biologics Inc. 220
11.16.1 Company Overview 220
11.16.2 Product Portfolio ; 220
11.16.3 Recent Development; 221
11.17 Smith And Nephew 222
11.17.1 Company Overview 222
11.17.2 Revenue Analysis 222
11.17.3 Product Portfolio 223
11.17.4 Recent Developments 223
11.18 Solsys Medical. 224
11.18.1 Company Overview 224
11.18.2 Product Portfolio 225
11.18.3 Recent Developments 225
11.19 Vericel Corporation. 226
11.19.1 Company Overview 226
11.19.2 1.1.2 Revenue Analysis 226
11.19.3 Product Portfolio 227
11.19.4 Recent Developments 227
11.20 Wright Medical Group N.V 228
11.20.1 Company Overview 228
11.20.2 1.1.2 Revenue Analysis 228
11.20.3 Product Portfolio 229
11.20.4 Recent Developments 230
12 Related Reports 231
?